13D Filing: Casdin Capital and Genmark Diagnostics Inc. (GNMK)

(a), (f)

This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company (“Casdin”), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), Casdin Partners GP, LLC, a Delaware limited liability company (the “GP”) and Eli Casdin, a United States citizen (collectively, the “Reporting Persons”).

(b)

The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2405, New York, New York 10019.

(c)

Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.

(d), (e)

During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.

13D Filing: Casdin Capital and Genmark Diagnostics Inc. (GNMK)

Published on March 28, 2018 at 10:14 am by Insider Monkey Staff in Hedge Funds

Page 6 of 11 – SEC Filing

Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)

Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on June 30, 2024 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

	The name of the issuer is GenMark Diagnostics, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is 5964 La Place Court, Carlsbad, California 92008-8829. This Schedule 13D relates to the Issuer’s Common Stock, $0.0001 par value (the “Shares”).

Item 3.	Source and Amount of Funds or Other Consideration.

	The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.